In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 10, 2017, Pages

  Pang, Yu ^a   Zong, Zhaojing ^a   Huo, Fengmin ^a   Jing, Wei ^a   Ma, Yifeng ^a   Dong, Lingling ^a   Li, Yunxu ^a   Zhao, Liping ^a   Fu, Yuhong ^a   Huang, Hairong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Bedaquiline; Delamanid; Extensively drug resistant tuberculosis; MIC; Minimal inhibitory concentration

Indexed keywords

AMIKACIN; BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; STREPTOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHINA; CODON; CROSS RESISTANCE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FBIC GENE; GENE IDENTIFICATION; GENE MUTATION; GYRA GENE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION;

ANTITUBERCULAR AGENTS; BEIJING; CHINA; CLOFAZIMINE; DIARYLQUINOLINES; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; HUMANS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES;

EID: 85029737600     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00900-17     Document Type: Article

References (35)

1. World Health Organization. 2016. Global tuberculosis report. WHO, Geneva, Switzerland.
2. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M. 2013. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 13:529–539. https://doi.org/10.1016/S1473-3099(13)70030-6.
3. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575–1580. https://doi.org/10.1016/S0140-6736(06)69573-1.
4. Dheda K, Gumbo T, Gandhi NR, Murray M, Theron G, Udwadia Z, Migliori GB, Warren R. 2014. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med 2:321–338. https://doi.org/10.1016/S2213-2600(14)70031-1.
5. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. 15 March 2017. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(17)30079-6.
6. Zumla A, Nahid P, Cole ST. 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12: 388–404. https://doi.org/10.1038/nrd4001.
7. Alcala L, Ruiz-Serrano MJ, Perez-Fernandez Turegano C, Garcia De Viedma D, Diaz-Infantes M, Marin-Arriaza M, Bouza E. 2003. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 47:416–417. https://doi.org/10.1128/AAC.47.1.416-417.2003.
8. Huang TS, Liu YC, Sy CL, Chen YS, Tu HZ, Chen BC. 2008. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother 52:2226 –2227. https://doi.org/10.1128/AAC.00414-07.
9. Koh WJ, Kang YR, Jeon K, Kwon OJ, Lyu J, Kim WS, Shim TS. 2012. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 67:1503–1507. https://doi.org/10.1093/jac/dks078.
10. Zhang Z, Pang Y, Wang Y, Liu C, Zhao Y. 2014. Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China. Int J Antimicrob Agents 43:231–235. https://doi.org/10.1016/j.ijantimicag.2013.12.007.
11. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE III. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 367:1508–1518. https://doi.org/10.1056/NEJMoa1201964.
12. Villar M, Sotgiu G, D’Ambrosio L, Raymundo E, Fernandes L, Barbedo J, Diogo N, Lange C, Centis R, Migliori GB. 2011. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 38:730–733. https://doi.org/10.1183/09031936.00195210.
13. Gopal M, Padayatchi N, Metcalfe JZ, O’Donnell MR. 2013. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 17:1001–1007. https://doi.org/10.5588/ijtld.12.0144.
14. Zhang Z, Li T, Qu G, Pang Y, Zhao Y. 2015. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 45:71–75. https://doi.org/10.1016/j.ijantimicag.2014.09.012.
15. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360:2397–2405. https://doi.org/10.1056/NEJMoa0808427.
16. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. 2012. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366:2151–2160. https://doi.org/10.1056/NEJMoa1112433.
17. World Health Organization. 2016. WHO treatment guidelines for drug-resistant tuberculosis update. WHO, Geneva, Switzerland.
18. Pang Y, Du J, Qin ZZ, Greenwald Z, Liu Y, Mi F, Zhao Y, Li L. 2016. An overview on tuberculosis-specific hospitals in China in 2009: results of a national survey. Eur Respir J 47:1584–1587. https://doi.org/10.1183/13993003.01854-2015.
19. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 51: 6–14. https://doi.org/10.1086/653115.
20. Li Y. 2014. China’s misuse of antibiotics should be curbed. BMJ 348: g1083. https://doi.org/10.1136/bmj.g1083.
21. Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. 2014. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother 58:364–369. https://doi.org/10.1128/AAC.01228-13.
22. Wei X, Zou G, Yin J, Walley J, Sun Q. 2013. Comparing patient care seeking pathways in three models of hospital and TB programme collaboration in China. BMC Infect Dis 13:93. https://doi.org/10.1186/1471-2334-13-93.
23. Pang Y, Zhang Z, Wang Y, Wang S, Song Y, Zhao B, Zhou Y, Ou X, Li Q, Xia H, Zheng Y, Fang X, Zhao Y. 2017. Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000 to 2010. Antimicrob Agents Chemother 61:e02170-16. https://doi.org/10.1128/AAC.02627-16.
24. Hartkoorn RC, Uplekar S, Cole ST. 2014. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:2979–2981. https://doi.org/10.1128/AAC.00037-14.
25. Feuerriegel S, Koser CU, Bau D, Rusch-Gerdes S, Summers DK, Archer JA, Marti-Renom MA, Niemann S. 2011. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother 55:5718–5722. https://doi.org/10.1128/AAC.05500-11.
26. Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, Wintjens R, Bifani P. 2015. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 59: 5316–5323. https://doi.org/10.1128/AAC.00308-15.
27. Yang C, Luo T, Shen X, Wu J, Gan M, Xu P, Wu Z, Lin S, Tian J, Liu Q, Yuan Z, Mei J, DeRiemer K, Gao Q. 2017. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis 17:275–284. https://doi.org/10.1016/S1473-3099(16)30418-2.
28. Perdigao J, Clemente S, Ramos J, Masakidi P, Machado D, Silva C, Couto I, Viveiros M, Taveira N, Portugal I. 2017. Genetic diversity, transmission dynamics and drug resistance of Mycobacterium tuberculosis in Angola. Sci Rep 7:42814. https://doi.org/10.1038/srep42814.
29. World Health Organization. 2008. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO, Geneva, Switzerland.
30. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, Xia H, Zhou Y, Li Q, Ou X, Pang Y, Song Y, Zhao B, Zhang H, He G, Guo J, Wang Y. 2012. National survey of drug-resistant tuberculosis in China. N Engl J Med 366: 2161–2170. https://doi.org/10.1056/NEJMoa1108789.
31. Zhang D, Wang Y, Lu J, Pang Y. 2015. In vitro activity of beta-lactams in combination with beta-lactamase inhibitors against multidrug-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 60: 393–399. https://doi.org/10.1128/AAC.01035-15.
32. EUCAST. Definitions of clinical breakpoints and epidemiological cut-off values. Clinical breakpoints table version 7.1. http://www.eucast.org/clinical_breakpoints/.
33. Schena E, Nedialkova L, Borroni E, Battaglia S, Cabibbe AM, Niemann S, Utpatel C, Merker M, Trovato A, Hofmann-Thiel S, Hoffmann H, Cirillo DM. 2016. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system. J Antimicrob Chemother 71:1532–1539. https://doi.org/10.1093/jac/dkw044.
34. Pang Y, Zhou Y, Zhao B, Liu G, Jiang G, Xia H, Song Y, Shang Y, Wang S, Zhao YL. 2012. Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China. PLoS One 7:e32976. https://doi.org/10.1371/journal.pone.0032976.
35. Almeida D, Ioerger T, Tyagi S, Li SY, Mdluli K, Andries K, Grosset J, Sacchettini J, Nuermberger E. 2016. Mutations in pepQ confer low-level resistance to bedaquiline and clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother 60:4590–4599. https://doi.org/10.1128/AAC.00753-16.